TOP > クイック検索 > 外国特許検索 > PHOSPHORYLATED SARM1, ANTIBODY, SARM1 PHOSPHORYLATION INHIBITOR, PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES, SCREENING METHOD, MODIFIED SARM1, AND USE

PHOSPHORYLATED SARM1, ANTIBODY, SARM1 PHOSPHORYLATION INHIBITOR, PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES, SCREENING METHOD, MODIFIED SARM1, AND USE NEW

外国特許コード F170009277
整理番号 (S2016-0511-N0)
掲載日 2017年11月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP011418
国際公開番号 WO 2017164230
国際出願日 平成29年3月22日(2017.3.22)
国際公開日 平成29年9月28日(2017.9.28)
優先権データ
  • 特願2016-058130 (2016.3.23) JP
発明の名称 (英語) PHOSPHORYLATED SARM1, ANTIBODY, SARM1 PHOSPHORYLATION INHIBITOR, PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES, SCREENING METHOD, MODIFIED SARM1, AND USE NEW
発明の概要(英語) The present invention provides a phosphorylated SARM1 (Sterile alpha and TIR motif-containing protein 1) in which at least one Ser residue selected from the group consisting of position 54, position 548, and position 622 of SARM1 is phosphorylated.
特許請求の範囲(英語) [claim1]
1. SARM1 (Sterile alpha and TIR motif-containing protein 1) The Ser residue of 1 where it is chosen from the group which consists of 54 rank, 548 rank and 622 rank kinds was phosphorylated at least, phosphorylation SARM1.
[claim2]
2. SARM1 is human origin, in claim 1 phosphorylation SARM1 of statement.
[claim3]
3. 54 rank, 548 rank or 622 rank of SARM1 the phosphorylation Ser residue is recognized uniquely, the non phosphorylation Ser residue of 54 rank, 548 rank or 622 rank of SARM1 is not recognized, the anti- phosphorylation SARM1 antibody.
[claim4]
4. The saikurin dependant kinase 8 (CDK8), the saikurin dependant kinase 19 (the CDK19) and SARM1 phosphorylation inhibiter which at least designates the inhibiter of 1 where it is chosen from the group which consists of JNK kinds as the active ingredient.
[claim5]
5. The saikurin dependant kinase 8 (CDK8), the saikurin dependant kinase 19 (CDK19) and the preventive of the nervous denaturation disease which at least designates the inhibiter of 1 where it is chosen from the group which consists of JNK kinds as the active ingredient or remedy.
[claim6]
6. The anti- SARM1 antibody, the SARM1 inhibiter which is chosen from the decoy peptide of SARM1 and the group which consists of the antagonist is designated as the active ingredient, the preventive of the nervous denaturation disease or remedy.
[claim7]
7. It is the anti- phosphorylation SARM1 antibody where the anti- SARM1 antibody, 54 rank, 548 rank or 622 rank of SARM1 phosphorylation control possibility 54 rank, recognizes 548 rank or 622 rank of antibody or SARM1 for non phosphorylation SARM1 the phosphorylation Ser residue uniquely, does not recognize the non phosphorylation Ser residue of 54 rank, 548 rank or 622 rank of SARM1, in claim 6 the preventive of the nervous denaturation disease of statement or remedy.
[claim8]
8. The decoy peptide of SARM1 Ser of SARM1 (54), Ser (548) or Ser (622) is fragmentary peptide or that decoration body which is included, in claim 6 the preventive of the nervous denaturation disease of statement or remedy.
[claim9]
9. The nervous denaturation disease the parkinson's disease, the muscle atrophy characteristic lateral column muscardine (ALS), the multiple sclerosis, either of the claim 5-8 which is chosen from the group which consists of niyuropachi and the Alzheimer's disease in 1 sections the preventive of the nervous denaturation disease of statement or remedy.
[claim10]
10. The process which at least detects the phosphorylation of the Ser residue of 1 where it is chosen from the group which consists of 54 rank, 548 rank and 622 rank of SARM1 kinds is included, screening method of the preventive of the nervous denaturation disease or remedy.
[claim11]
11. The process which at least detects the phosphorylation of the Ser residue of 1 where it is chosen from the group which consists of 54 rank, 548 rank and 622 rank of SARM1 kinds is included, screening method of the SARM1 inhibiter.
[claim12]
12. Person SARM1 54th, 548th and the SARM1 reforming transformation where Ser which at least is suitable to 1 where it is chosen from the group which consists of 622nd kinds is substituted with Glu or Asp.
[claim13]
13. In model cell of nervous denaturation disease or claim 12 for drawing up the model animal use of SARM1 reforming transformation of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OKAYAMA UNIVERSITY
  • 発明者(英語)
  • MURATA HITOSHI
  • SAKAGUCHI MASAKIYO
  • KINOSHITA RIE
  • YAMAMOTO KENICHI
国際特許分類(IPC)
指定国 (WO2017164230)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close